73 related articles for article (PubMed ID: 29069746)
21. WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects.
Guan F; Ding R; Zhang Q; Chen W; Li F; Long L; Li W; Li L; Yang D; Xie L; Yuan S; Wang L
Oncotarget; 2017 Sep; 8(42):71782-71796. PubMed ID: 29069746
[TBL] [Abstract][Full Text] [Related]
22. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
23. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.
Nicholson B; Lloyd GK; Miller BR; Palladino MA; Kiso Y; Hayashi Y; Neuteboom ST
Anticancer Drugs; 2006 Jan; 17(1):25-31. PubMed ID: 16317287
[TBL] [Abstract][Full Text] [Related]
24. A novel colchicine-based microtubule inhibitor exhibits potent antitumor activity by inducing mitochondrial mediated apoptosis in MIA PaCa-2 pancreatic cancer cells.
Kumar A; Singh B; Mahajan G; Sharma PR; Bharate SB; Mintoo MJ; Mondhe DM
Tumour Biol; 2016 Oct; 37(10):13121-13136. PubMed ID: 27449046
[TBL] [Abstract][Full Text] [Related]
25. 5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f), a new synthetic compound, causes human fibrosarcoma HT-1080 cell apoptosis by disrupting tubulin polymerisation and inducing G2/M arrest.
Zuo D; Pang L; Shen J; Guan Q; Bai Z; Zhang H; Li Y; Lu G; Zhang W; Wu Y
Int J Oncol; 2017 Jun; 50(6):2069-2078. PubMed ID: 28440465
[TBL] [Abstract][Full Text] [Related]
26. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
Meng F; Cai X; Duan J; Matteucci MG; Hart CP
Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
[TBL] [Abstract][Full Text] [Related]
27. Dynamic cytotoxic profiles of sulfur mustard in human dermal cells determined by multiparametric high-content analysis.
Long L; Li W; Chen W; Li FF; Li H; Wang LL
Toxicol Res (Camb); 2016 Mar; 5(2):583-593. PubMed ID: 30090372
[TBL] [Abstract][Full Text] [Related]
28. Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing.
Zhang QI; Wang S; Yang D; Pan K; Li L; Yuan S
Oncol Lett; 2016 May; 11(5):3265-3272. PubMed ID: 27123101
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.
Kampan NC; Madondo MT; McNally OM; Quinn M; Plebanski M
Biomed Res Int; 2015; 2015():413076. PubMed ID: 26137480
[TBL] [Abstract][Full Text] [Related]
30. Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
Klute K; Nackos E; Tasaki S; Nguyen DP; Bander NH; Tagawa ST
Onco Targets Ther; 2014; 7():2227-36. PubMed ID: 25506226
[TBL] [Abstract][Full Text] [Related]
31. Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.
Wang XF; Guan F; Ohkoshi E; Guo W; Wang L; Zhu DQ; Wang SB; Wang LT; Hamel E; Yang D; Li L; Qian K; Morris-Natschke SL; Yuan S; Lee KH; Xie L
J Med Chem; 2014 Feb; 57(4):1390-402. PubMed ID: 24502232
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes.
Garside H; Marcoe KF; Chesnut-Speelman J; Foster AJ; Muthas D; Kenna JG; Warrior U; Bowes J; Baumgartner J
Toxicol In Vitro; 2014 Mar; 28(2):171-81. PubMed ID: 24189122
[TBL] [Abstract][Full Text] [Related]
33. Drug discovery: Rethinking cellular drug response.
Jenkins JL
Nat Chem Biol; 2013 Nov; 9(11):669-70. PubMed ID: 24141220
[No Abstract] [Full Text] [Related]
34. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
